Thursday, January 29, 2015

MAIN ARENA 1

08:00 – 09:30  Innovative approaches and hot topics in endovascular interventions

CHAIRMAN:
Lawrence Garcia

MODERATOR:
Koen Deloose
Josef Tacke
Michael Lichtenberg
William Gray
Sigrid Nikol
Lieven Maene
Erich Minar

08:00 – 08:05  Does stent design influence the results of SFA stenting?
Koen Deloose

08:05 – 08:10  New approaches for drug-eluting stents: The NitiDES programme
Dierk Scheinert

08:10 – 08:25  Recorded case via satellite from Münster

08:25 – 08:30  Results from the Freeway Stent study
Josef Tacke

08:30 – 08:35  ILLUMENATE Direct: 12 months results with direct DCB use in femoropopliteal arteries
Stephan Duda

08:35 – 08:40  Next generation DCB coating–the EffPac-trial
Sebastian Sixt

08:40 – 09:00  Live case transmission from Bad Krozingen

09:00 – 09:05  RELINE-trial: 24 months results with the Viabahn vs. PTA for in-stent restenosis
Koen Deloose

09:05 – 09:10  The role of DCB for SFA-ISR
Yann Gouëffic

09:10 – 09:15  First experience with DCB in AV-fistulas
Stephan Duda

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15 – 09:20</td>
<td>The utility of carbon-dioxide angiography in peripheral interventions</td>
</tr>
<tr>
<td></td>
<td>Ulf Teichgräber</td>
</tr>
<tr>
<td>09:20 – 09:25</td>
<td>Using ARROW GPSCath to protect wire placement, reduce fluoroscopy while minimizing contrast</td>
</tr>
<tr>
<td></td>
<td>Michael Lichtenberg</td>
</tr>
<tr>
<td>09:25 – 09:30</td>
<td>Discussion and conclusion</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.
Thursday, January 29, 2015

DISCUSSION FORUM

12:30 – 13:30  The great debate: Are all DCB equal?
CHARMAN: Michael Jaff
Dierk Scheinert
DISCUSSANT:
Gunnar Tepe
Renu Virmani
Stephan Duda
Marianne Brodmann

12:30 – 12:37  There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!
Gunnar Tepe

12:37 – 12:44  Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges – Results have been substantially affected by trial design
Renu Virmani

12:44 – 12:51  The relevance of Paclitaxel dose and coating for efficacy and safety
Renu Virmani

12:51 – 12:58  Whats next to come in the drug delivery space: Ongoing DCB programmes
Stephan Duda

12:58 – 13:05  Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions
Erich Minar

13:05 – 13:12  DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are continuing
Marianne Brodmann

13:12 – 13:30  Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.